About developer

This author has not yet filled in any details.
So far developer has created 63 blog entries.

Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment with BL8040

BioLineRx Presented Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment with BL8040 at European Hematology Association Conference. BL-8040’s rapid stem-cell mobilization supports stand-alone one-day treatment for stem-cell collection. Graft derived from BL-8040 treatment shows unique cell composition.

Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment with BL80402021-06-03T06:04:43+00:00

Initiation of Phase 2b Trial for Novel AML Consolidation Treatment with BL8040

BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment  Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, will enroll up to 194 patients, randomized in 1:1 ratio, at up to 25 sites in Germany 

Initiation of Phase 2b Trial for Novel AML Consolidation Treatment with BL80402021-06-03T06:04:22+00:00

Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions, hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA) with BL8040

"BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions Efficacy and safety study, in collaboration with MD Anderson Cancer Center, will assess BL-8040 as combination treatment with immunosuppressants Interim results of study, in patients with hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA), expected by end of 2016"

Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions, hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA) with BL80402021-06-03T06:01:55+00:00

BioLineRx Announces Collaboration with MSD to investigate the combination of KEYTRUDA® (pembrolizumab) and BL-8040 in Pancreatic Cancer

BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx’s BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer.

BioLineRx Announces Collaboration with MSD to investigate the combination of KEYTRUDA® (pembrolizumab) and BL-8040 in Pancreatic Cancer2021-06-03T06:01:40+00:00

BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML

BioLineRx (NASDAQ/TASE: BLRX) announced today positive top-line results from BL-8040’s Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia . Data also identify a potential biomarker for future selection of BL-8040-responsive AML patients

BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML2021-06-03T06:01:14+00:00

BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications

BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced that it has entered into a collaboration with Genentech, a member of the Roche Group, to support several Phase 1b studies investigating BioLineRx’s BL-8040 in combination with Atezolizumab, Genentech’s anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of [...]

BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications2021-06-03T06:01:03+00:00

BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination with KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer

Tel Aviv, Israel, September 20, 2016 - BioLineRx Ltd. (NASDAQ/TASE:BLRX) today announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer.The Phase 2a study, named the COMBAT study, is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy [...]

BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination with KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer2021-06-03T06:00:49+00:00
Go to Top